Article

Managing Side Effects of mTOR Inhibitors in Cancer

Naomi Haas, of the Abramson Cancer Center, explains the potential side effects of a class of drugs called mTOR inhibitors, primarily the agents Sutent and Nexavar.

Naomi Haas, of the Abramson Cancer Center, explains the potential side effects of a class of drugs called mTOR inhibitors, primarily the agents Sutent (sunitinib) and Nexavar (sorafenib). mTOR inhibitors target the blood vessels, but they also have other effects, Haas says.

Common side effects may include high blood pressure, fatigue, diarrhea and hand-foot syndrome.

"They are actually very manageable if they are reported early," she says. "What I recommend is that patients go over these side effects up front. We encourage patients to monitor their blood pressure. We encourage them to call early if they get any signs of these symptoms or discomfort." Dose adjustments and supportive care are two ways to manage potential side effects, she notes.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Related Content